Table 2.
Clinical characteristics and CSF data of subjects with amyloid PET (n = 177)
| Characteristics | Total | Normal (n = 87) |
aMCI (n = 56) |
AD dementia (n = 34) |
|||
|---|---|---|---|---|---|---|---|
| PET negative | PET positive (preclinical AD] | PET negative | PET positive (prodromal AD] | PET negative | PET positive | ||
| Subjects, n | 177 | 73 | 14 | 29 | 27 | 3 | 31 |
| Age, years | 177 | 71.6 (5.9) | 72.5 (5.5) | 72.4 (7.2) | 70.6 (8.9) | 71.7 (8.4) | 69.2 (5.8) |
| Education, years | 177 | 9.6 (5.0) | 9.9 (5.3) | 9.8 (4.4) | 8.2 (5.0) | 9.3 (5.8) | 6.8 (3.7) |
| Female sex | 177 | 39 (53.4%] | 7 (50.0%] | 13 (44.8%] | 13 (48.1%) | 0 (0.0%] | 19 (61.3%] |
| APOE ∊ 4 carrier status | 175 | 14 (19.2%) | 8 (57.1%) | 6 (20.7%) | 18 (66.7%) | 0 (0.0%) | 20 (64.5%) |
| K-MMSE score, points | 177 | 26.6 (2.6) | 27.1 (2.9) | 25.4 (3.5) | 25.5 (3.8) | 23.0 (2.6) | 18.1 (5.4) |
| CDR | 177 | 0.3 (0.2) | 0.3 (0.3) | 0.5 (0.0) | 0.5 (0.0) | 0.5 (0.0)* | 0.8 (0.4)* |
| CDR sum of boxes | 177 | 0.5 (0.7) | 0.4 (0.4) | 1.2 (0.8) | 1.3 (0.6) | 1.7 (0.3)** | 4.8 (2.6)** |
| GDS | 177 | 1.6 (0.5) | 1.6 (0.5) | 2.9 (0.3) | 3.0 (0.2) | 3.0 (0.0)* | 4.0 (0.9)* |
| B-ADL | 177 | 20.0 (0.0) | 20.0 (0.0) | 20.0 (0.2) | 20.0 (0.2) | 20.0 (0.0) | 19.0 (1.7) |
| I-ADL | 177 | 0.05 (0.09) | 0.04 (0.07) | 0.13 (0.16)** | 0.24 (0.14) ** | 0.45 (0.00)* | 0.62 (0.20)* |
| CSFA β1–42 levels, pg/mL | 177 | 1,047.5 (186.6)* | 643.0 (171.1)* | 978.4 (249.2)* | 548.2 (214.9)* | 1,306.8 (269.0)* | 486.7 (200.7)* |
| CSFA β1–40 levels, pg/mL | 177 | 10,219.8 (4,668) | 9,600.5 (5,066) | 8,370.7 (4,132) | 7,852.0 (2,802) | 10,313.2 (3,939) | 7,021.1 (3,717) |
| CSF t-Tau levels, pg/mL | 177 | 237.8 (97.2)** | 300.6 (132.0)** | 250.4 (220.5) | 361.3 (229.4) | 270.3 (131.5) | 508.5 (215.0) |
| CSF p-Tau 181 levels, pg/mL | 177 | 46.2 (17.1) | 55.1 (20.9) | 44.4 (24.9)** | 62.4 (32.3)** | 54.1 (25.2) | 74.3 (28.1) |
Data are presented as mean (standard deviation] or n (%) unless indicated otherwise. A β, beta-amyloid protein; AD, Alzheimer's disease; aMCI, amnestic mild cognitive impairment; APOE, apolipoprotein E; B-ADL, basic activities of daily living; CDR, Clinical Dementia Rating; CSF, cerebrospinal fluid; GDS, Global Deterioration Scale; I-ADL, instrumental activities of daily living; K-MMSE, Korean version of the Mini-Mental State Examination; PET, positron emission tomography; p-Tau 181, tau protein phosphorylated at threonine 181; t-Tau, total tau protein.
*
p < 0.001,
**
p < 0.05.